Are you old enough to remember the “good old days” of perusing the dusty bound medical journals, looking for an article or guideline you needed? I don’t miss traipsing across campus to search up and down the stacks of the library.
Each Wednesday, I bring you news concerning updates to guidelines and recommendations by professional societies, so you don’t have to go “traipsing” through the electronic journals. This list is not all-inclusive, of course, but the following recent updates caught my attention.
If there are any guidelines I have missed this week that you would like to see possibly included in future updates, please email me at jerm@day-storms.com. You can check out earlier updates here.
National Cancer Comprehensive Network (NCCN)
The NCCN guidelines can be found at www.nccn.org.
Soft Tissue Sarcoma Version 5.2024
In this update to the NCCN guidelines, vimseltinib has been added as category 1 recommendation for the treatment of tenosynovial giant cell tumor/pigmented villonodular synovitis.
Systemic Light Chain Amyloidosis Version 2.2025
The discussion section has been modified to align with algorithm changes.
Uterine Neoplasms Version 3.2025
In this update, the NCCN has modified the discussion section to reflect algorithm changes. Also, within the section on systemic therapy for endometrial carcinoma, the NCCN has clarified that the listed therapeutics may be used as a subsequent therapy if they were not used previously.
Wilms Tumor (Nephroblastoma) Version 1.2025
Referral to pediatric oncology specialists is now recommended for adult patients, as their treatment should align with pediatric protocols. Fertility preservation counseling is strongly recommended before initiating intensive chemotherapy or whole abdominal irradiation. The guidelines refine risk stratification strategies, highlighting that patients with very low-risk favorable histology Wilms tumor (FHWT) and adverse biomarkers (e.g., 1q gain, combined LOH at 1p and 16q) may not be candidates for treatment de-escalation. Updates in radiation therapy stress minimizing field overlap for abdominal and lung radiation. Additionally, adjuvant chemotherapy regimens for Stage IV Wilms tumor with focal anaplasia have been revised, switching to revised regimen UH-1 instead of UH-2.
European Society for Vascular Surgery (ESVS)
The ESVS 2025 guidelines on the management of vascular trauma include recommendations for rapid access to specialized vascular teams with hybrid surgical capabilities, damage control resuscitation, and massive transfusion protocols. Early administration of tranexamic acid is recommended for severe hemorrhage. CT angiography is the first-line diagnostic tool, while immediate surgical exploration is advised for hemodynamically unstable patients. Additionally, vascular shunts should be used when immediate repair is not feasible, and tourniquets remain critical for extremity trauma with uncontrolled bleeding.
American College of Gastroenterology (ACG)
Recently, the ACG published comprehensive guidelines concerning gastric premalignant conditions (GPMC) including recommendations on the diagnosis, surveillance, and management of atrophic gastritis, gastric intestinal metaplasia (GIM), dysplasia, and gastric epithelial polyps. Routine upper endoscopic screening for gastric cancer (GC) and GPMC is not recommended for the general U.S. population due to insufficient evidence. However, endoscopic surveillance every three years is suggested for high-risk individuals, including those with GIM and risk factors such as corpus involvement, incomplete histology, family history of GC, or high-risk racial/ethnic background (East Asian, Latino/a, Black, and AIAN individuals). H. pylori testing and eradication are strongly recommended in all patients with GPMC. The guidelines also emphasize high-quality endoscopic evaluation with image-enhanced endoscopy, systematic biopsies, and risk stratification based on histologic subtypes. Endoscopic resection is advised for gastric adenomas.
American Association for Cancer Research (AACR)
The AACR updates to the Guidelines for Cancer Screening in Individuals with Li-Fraumeni Syndrome (LFS) is based on evolving evidence from the Toronto Protocol and emerging genotype-phenotype correlations. Key updates include annual whole-body MRI from birth, with dedicated annual brain MRI screening, which may be performed 6 months apart from the whole-body MRI. Breast cancer surveillance now emphasizes annual MRI starting at age 20, with mammography added at age 30, while colonoscopy is recommended every 2–3 years beginning at age 25. Pancreatic cancer screening is advised only for individuals with a family history. Liquid biopsy for early tumor detection is under investigation.
This is for informational purposes only. Publication does not constitute endorsement by Day-Storms, LLC or its employees of any particular product or service offered by a company, association, or society listed within the publication. To learn more about Day-Storms, LLC, please check out our Services Provided.
Jerm Day-Storms, PhD, MWC
Contact me: jerm@day-storms.com | (863) 279-7910
Copyright 2025 Day-Storms, LLC